Bicara Therapeutics IPO

Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.

Register for Details

For more details on financing and valuation of private companies similar to Bicara Therapeutics before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Bicara Therapeutics

To invest in Bicara Therapeutics pre-IPO

Can you invest in Bicara Therapeutics pre-IPO?

You may invest in Bicara Therapeutics as it is a public company listed on the NASDAQ with ticker BCAX. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Bicara Therapeutics before it goes public?

You can no longer sell shares of Bicara Therapeutics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Bicara Therapeutics shares?

Forge can no longer determine the value of Bicara Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Bicara Therapeutics a publicly traded company?

Bicara Therapeutics became a public company following its IPO on 09/13/2024 and is now traded on the NASDAQ under the ticker BCAX.

To learn more about Bicara Therapeutics potential IPO

Will Bicara Therapeutics go IPO?

Bicara Therapeutics became a public company following its IPO on 09/13/2024 and is now traded on the NASDAQ under the ticker BCAX.

What is Bicara Therapeutics’ IPO price?

The IPO price of Bicara Therapeutics is not currently available.

When was Bicara Therapeutics founded?

Bicara Therapeutics was founded in 2020.

What is Bicara Therapeutics funding to date?

Bicara Therapeutics has raised $710.05MM to date.

Who are Bicara Therapeutics’s major investors?

Vedanta Capital
Omega Funds
F-Prime Capital
Premji Invest
Deerfield Management
Aisling Capital
Acorn Bioventures
Invus Piper Heartland Healthcare Capital
Fairmount
Eight Roads Ventures
Tpg
Janus Henderson Investors
Braidwell Lp
Piper Heartland Healthcare Capital
The Invus Group
Ra Capital Management
Invus
Braidwell
Red Tree Venture Capital
Bioqube Ventures
Impactassets
Fairmount Partners
The Rise Fund
Biocon

Bicara Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/12/2023 Series C $165MM $xx.xx $495.55MM Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg
Price per Share
$xx.xx
Shares Outstanding
119,599,872
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Aisling Capital, Bioqube Ventures, Braidwell Lp, Deerfield Management, Eight Roads Ventures, Fairmount, F-Prime Capital, Invus Piper Heartland Healthcare Capital, Janus Henderson Investors, Omega Funds, Premji Invest, Ra Capital Management, Red Tree Venture Capital, The Rise Fund, Tpg
03/06/2023 Series B $108.23MM $xx.xx $274.39MM Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital
Price per Share
$xx.xx
Shares Outstanding
105,595,101
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, F-Prime Capital, Invus, Janus Henderson Investors, Omega Funds, Piper Heartland Healthcare Capital, Premji Invest, Ra Capital Management, Red Tree Venture Capital
03/15/2021 Series Seed $81.79MM $xx.xx $136.32MM Biocon
Price per Share
$xx.xx
Shares Outstanding
81,790,144
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Biocon
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.